| Literature DB >> 30410032 |
Dan-Dan Li1, Tao Xu2, Xin-Qi Cheng1, Wei Wu1, Yi-Cong Ye3, Xiu-Zhi Guo1, Qian Cheng1, Qian Liu1, Li Liu1, Guang-Jin Zhu4, Jie Wu5, Ling Qiu6.
Abstract
Serum gamma-glutamyltransferase (GGT), which is mainly derived from the liver, is a sensitive marker of liver cell damage and oxidative stress. More recently, it has been found that increased GGT plasma activity is also associated with cardiovascular disease (CVD). However, data on the relationship between GGT and cardiovascular risk factors (CRFs) are lacking in nationally representative samples of the Chinese population. Here, we aim to investigate both the association between GGT and CRFs and CRF clustering. A cross-sectional survey was conducted in a representative sample of 22897 adults aged 18 years and older from 2007 to 2011 nationally, which included a plurality of ethnic minorities. The participants were then divided into quartiles of sex-specific serum GGT. From the low to high GGT quartiles, the incidence of each CRF and clustered risk factors increased after adjusting for age, uric acid (UA), ethnicity, drinking, and all other risk factors. Individuals in the upper stratum (>75th percentile) had higher prevalence rates of CRFs than did those in the lower stratum (all P < 0.05). Furthermore, the subjects with clustering of 1, 2, or ≥3 CRFs were still more likely to belong to the upper GGT quartiles (75th percentiles) than were those without risk factors (all P < 0.05). In conclusion, our data highlight that there is an association between higher serum GGT levels and prevalence of CRFs, which tend to cluster with the increase in GGT activity in Chinese adults.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30410032 PMCID: PMC6224435 DOI: 10.1038/s41598-018-34913-7
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1A schematic used for screening and inclusion of study samples. The final sample size was 22897, which consisted of 10715 men and 12182 women. BP = blood pressure.
Baseline characteristics of individuals according to sex-specific quartiles of GGT.
| Men | P valuea | Women | P valueb | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Q1(<17 U/L) | Q2(17–25 U/L) | Q3(25–43 U/L) | Q4(>43 U/L) | Q1(<11 U/L) | Q2(11–15 U/L) | Q3(15–23 U/L) | Q4(>23 U/L) | |||
| n | 2624 | 2617 | 2801 | 2673 | 2502 | 3253 | 3262 | 3165 | ||
| Age | 33 (22–56) | 42 (27–59) | 46 (35–59) | 44 (36–54) | <0.001 | 34 (25–44) | 39 (27–52) | 46 (34–58) | 51 (42–60) | <0.001 |
| BMI (kg/m2) | 21.8 ± 2.73 | 23.1 ± 3.17 | 24.6 ± 3.28 | 26.0 ± 3.43 | <0.001 | 21.7 ± 2.57 | 22.4 ± 2.97 | 23.6 ± 3.37 | 24.8 ± 3.62 | <0.001 |
| WC (cm) | 75.8 ± 8.3 | 80.0 ± 9.4 | 84.5 ± 9.6 | 88.8 ± 9.5 | <0.001 | 71.9 ± 7.5 | 74.2 ± 8.9 | 77.9 ± 9.4 | 81.8 ± 9.7 | <0.001 |
| SBP (mmHg) | 122.8 ± 15.7 | 127.1 ± 16.9 | 130.0 ± 17.6 | 131.9 ± 17.1 | <0.001 | 116.1 ± 15.5 | 120.0 ± 17.1 | 125.7 ± 19.5 | 130.8 ± 20.9 | <0.001 |
| DBP (mmHg) | 75.4 ± 10.3 | 78.7 ± 10.8 | 81.6 ± 10.9 | 84.5 ± 11.4 | <0.001 | 74.0 ± 10.0 | 76.1 ± 10.2 | 79.1 ± 10.8 | 81.8 ± 11.5 | <0.001 |
| UA (μmol/L) | 322.7 ± 76.9 | 332.7 ± 77.5 | 350.1 ± 83.7 | 376.3 ± 86.8 | <0.001 | 239.5 ± 57.1 | 245.9 ± 62.1 | 261.7 ± 64.5 | 283.2 ± 73.9 | <0.001 |
| FBG (mmol/L) | 5.14 ± 0.78 | 5.27 ± 1.47 | 5.49 ± 1.31 | 5.73 ± 1.48 | <0.001 | 5.04 ± 0.61 | 5.16 ± 0.79 | 5.35 ± 1.03 | 5.71 ± 1.49 | <0.001 |
| TG (mmol/L) | 0.89 (0.65–1.21) | 1.11 (0.80–1.57) | 1.43 (1.01–2.12) | 2.08 (1.37–3.17) | <0.001 | 0.84 (0.63–1.15) | 0.98 (0.72–1.34) | 1.21 (0.87–1.76) | 1.55 (1.09–2.30) | <0.001 |
| TC (mmol/L) | 4.14 ± 0.91 | 4.47 ± 0.93 | 4.78 ± 0.96 | 5.17 ± 1.11 | <0.001 | 4.27 ± 0.85 | 4.52 ± 0.93 | 4.84 ± 1.00 | 5.16 ± 1.06 | <0.001 |
| HDL-C (mmol/L) | 1.33 ± 0.32 | 1.31 ± 0.33 | 1.27 ± 0.34 | 1.26 ± 0.35 | <0.001 | 1.50 ± 0.33 | 1.48 ± 0.34 | 1.45 ± 0.34 | 1.42 ± 0.36 | <0.001 |
| LDL-C (mmol/L) | 2.39 ± 0.78 | 2.62 ± 0.80 | 2.83 ± 0.83 | 2.93 ± 0.89 | <0.001 | 2.37 ± 0.75 | 2.53 ± 0.81 | 2.78 ± 0.83 | 2.99 ± 0.90 | <0.001 |
| Cr (mg/dL) | 80.7 ± 19.0 | 82.5 ± 15.2 | 83.5 ± 15.3 | 82.4 ± 15.8 | <0.001 | 63.1 ± 14.9 | 62.9 ± 15.2 | 63.9 ± 13.1 | 65.0 ± 14.0 | <0.001 |
| Urea (mg/dL) | 5.14 ± 1.49 | 5.27 ± 1.47 | 5.33 ± 1.47 | 5.24 ± 1.43 | <0.001 | 4.54 ± 1.32 | 4.62 ± 1.42 | 4.83 ± 1.44 | 4.96 ± 1.43 | <0.001 |
| eGFR (mL/min/173 m2) | 104.0 ± 21.4 | 98.3 ± 19.1 | 95.1 ± 17.4 | 97.1 ± 16.3 | <0.001 | 105.7 ± 19.7 | 103.4 ± 20.2 | 98.2 ± 19.5 | 93.4 ± 19.9 | <0.001 |
| GGT (U/L) | 13.2 (11.0–15.0) | 20.1 (18.5–22.1) | 31.4 (28.0–36.2) | 66.4 (51.5–98.9) | <0.001 | 9.0 (8.0–10.0) | 12.7 (11.8–13.6) | 17.7 (16.0–20.0) | 34.1 (27.0–52.0) | <0.001 |
| Drinking | 730 (27.8%) | 926 (35.4%) | 1225 (43.7%) | 1575 (58.7%) | <0.001 | 104 (4.3%) | 154 (4.7%) | 159 (5.1%) | 209 (6.6%) | <0.001 |
| Dyslipidemia | 795 (30.3%) | 1192 (45.5%) | 172 (61.5%) | 2125 (79.5%) | <0.001 | 582 (23.3%) | 1083 (33.3%) | 1645 (50.4%) | 2108 (66.6%) | <0.001 |
| Hypertension1 | 402 (15.3%) | 618 (23.6%) | 868 (31.0%) | 1016 (38.0%) | <0.001 | 255 (10.2%) | 488 (15.0%) | 809 (24.8%) | 1082 (34.2%) | <0.001 |
| Hypertension2 | 875 (33.3%) | 1156 (44.2%) | 1585 (56.6%) | 1798 (67.3%) | <0.001 | 671 (26.8%) | 1082 (33.3%) | 1505 (46.1%) | 1773 (56.0%) | <0.001 |
| Diabetes | 59 (2.2%) | 90 (3.4%) | 149 (5.3%) | 223 (8.3%) | <0.001 | 9 (0.4%) | 52 (1.6%) | 111 (3.4%) | 278 (8.8%) | <0.001 |
| Current smoking | 883 (33.7%) | 1041 (39.8%) | 1226 (45.2%) | 1335 (49.9%) | <0.001 | 46 (1.8%) | 71 (2.2%) | 93 (2.9%) | 130 (4.21%) | <0.001 |
| Overweight | 343 (13.1%) | 718 (27.4%) | 1268 (45.3%) | 1614 (60.4%) | <0.001 | 261 (10.4%) | 595 (18.3%) | 1056 (32.4%) | 1469 (46.4%) | <0.001 |
Data are shown as the mean ± standard deviation (SD), n (%); GGT, TG, and age were reported as medians (interquartile range). WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; UA, uric acid; TG, triglyceride; TC, total cholesterol; FBG, fasting blood glucose; HDL-C, high density lipoprotein cholesterol; LDLC, low density lipoprotein cholesterol; Cr, creatinine; GGT, gamma—glutamyltransferase; eGFR, estimated glomerular filtration rate. aquartiles of comparison in men; bquartiles of comparison in women.
1The prevalence of hypertension defined with JNC7 according to sex-specific quartiles of GGT.
2The prevalence of hypertension defined with 2017 ACC/AHA according to sex-specific quartiles of GGT.
Composition ratio of the sex-specific GGT <75th and GGT ≥75th among the study population for different groups.
| Men (n = 10715) | P value | Women (n = 12182) | P value | |||
|---|---|---|---|---|---|---|
| GGT <75th | GGT ≥75th | GGT <75th | GGT ≥75th | |||
| overall | 8042 (75.1%) | 2673 (24.9%) | 9017 (74.0%) | 3165 (26.0%) | ||
| Age group (years) | <0.001* | <0.001* | ||||
| 18–34 | 3048 (83.6%) | 600 (16.4%) | 3422 (90.4%) | 354 (9.6%) | ||
| 35–44 | 1320 (62.7%) | 784 (37.3%) | 2025 (74.9%) | 677 (25.1%) | ||
| 45–54 | 1226 (64.1%) | 686 (35.9%) | 1526 (64%) | 858 (36.0%) | ||
| 55–64 | 1262 (77.6%) | 364 (22.4%) | 1223 (61.6%) | 764 (38.4%) | ||
| ≥65 | 1186 (83.2%) | 239 (16.8%) | 821 (62.1%) | 502 (37.9%) | ||
| Regions | <0.001# | <0.001# | ||||
| South | 4345 (78.6%) | 1181 (21.4%) | 4613 (76.0%) | 1457 (24.0%) | ||
| North | 3697 (71.2%) | 1492 (28.8%) | 4404 (72.1%) | 1708 (27.9%) | ||
| Cities | <0.001# | <0.001# | ||||
| Urban | 3567 (79.5%) | 921 (20.5%) | 3823 (75.9%) | 1216 (24.1%) | ||
| Rural | 4475 (71.9%) | 1752 (28.1%) | 5194 (72.7%) | 1949 (27.3%) | ||
| Ethnic group | <0.001* | <0.001* | ||||
| Han | 5319 (76.8%) | 1610 (23.2%) | 5738 (74.0%) | 2014 (26.0%) | ||
| Yi | 631 (70.3%) | 266 (29.7%) | 815 (72.3%) | 313 (27.7%) | ||
| Hui | 796 (80.9%) | 188 (19.1%) | 700 (76.4%) | 216 (23.6%) | ||
| Mongolian | 286 (58.4%) | 204 (41.6%) | 496 (68.1%) | 232 (31.9%) | ||
| Korean | 230 (65.0%) | 124 (35.0%) | 398 (74.0%) | 140 (26.0%) | ||
| Tibetan | 226 (71.5%) | 90 (26.0%) | 349 (76.4%) | 108 (23.6%) | ||
| Tujia | 268 (74.0%) | 94 (26.0%) | 237 (80.9%) | 56 (19.1%) | ||
| Miao | 162 (73.0%) | 60 (27.0%) | 146 (76.8%) | 44 (23.2%) | ||
| Other | 124 (77.0%) | 37 (23.0%) | 138 (76.7%) | 42 (23.3%) | ||
*P-values were significant (<0.05) among groups.
#P-values were significant (<0.05) between groups.
Prevalence of clustered CRFs among participants in the GGT <75th and GGT ≥75th percentiles by gender and age. Data are presented as N (percent prevalence).
| Clustered CRFs | Men | P-valuea | Women | P-valueb | ||
|---|---|---|---|---|---|---|
| GGT <75th | GGT ≥75th | GGT <75th | GGT ≥75th | |||
|
| ||||||
| overall | 1815 (22.6%) | 122 (4.6%) | <0.001 | 4379 (48.6%) | 554 (17.5%) | <0.001 |
| ≥ | ||||||
| overall | 6227 (77.4%) | 2551 (95.4%) | <0.001 | 4638 (51.4%) | 2611 (82.5%) | <0.001 |
| 18–34 | 1871 (61.4%) | 562 (93.7%) | <0.001 | 836 (25.2%) | 177 (52.8%) | <0.001 |
| 35–44 | 1111 (84.2%) | 763 (97.3%) | <0.001 | 980 (48.4%) | 504 (74.4%) | <0.001 |
| 45–54 | 1091 (89.0%) | 659 (96.1%) | <0.001 | 1106 (72.5%) | 747 (87.1%) | <0.001 |
| 55–64 | 1121 (88.8%) | 348 (95.6%) | <0.001 | 1024 (83.7%) | 712 (93.2%) | <0.001 |
| ≥65 | 1033 (87.1%) | 219 (91.6%) | 0.050 | 692 (84.3%) | 471 (93.8%) | <0.001 |
| ≥ | ||||||
| overall | 3492 (43.4%) | 2122 (79.4%) | <0.001 | 1905 (21.1%) | 1659 (52.4%) | <0.001 |
| 18–34 | 679 (22. 3%) | 451 (75.2%) | <0.001 | 132 (4.0%) | 70 (20.9%) | <0.001 |
| 35–44 | 662 (50.2%) | 638 (81.4%) | <0.001 | 315 (15.6%) | 261 (38.6%) | <0.001 |
| 45–54 | 713 (58.2%) | 568 (82.8%) | <0.001 | 503 (33.0%) | 455 (53.0%) | <0.001 |
| 55–64 | 756 (59.9%) | 293 (80.5%) | <0.001 | 548 (44.8%) | 518 (67.8%) | <0.001 |
| ≥65 | 682 (57.5%) | 172 (72.0%) | <0.001 | 407 (49.6%) | 355 (70.7%) | <0.001 |
| ≥ | ||||||
| overall | 1344 (16.7%) | 1252 (46.8%) | <0.001 | 526 (5.8%) | 682 (21.5%) | 0.001 |
| 18–34 | 176 (5.8%) | 251 (41.8%) | <0.001 | 10 (0.3%) | 19 (5.7%) | <0.001 |
| 35–44 | 236 (17.9%) | 383 (48.9%) | <0.001 | 60 (3.0%) | 91 (13.4%) | <0.001 |
| 45–54 | 302 (24.6%) | 352 (51.3%) | <0.001 | 130 (8.5%) | 163 (19.0%) | <0.001 |
| 55–64 | 335 (26.5%) | 172 (47.3%) | <0.001 | 180 (14.7%) | 227 (29.7%) | <0.001 |
| ≥65 | 295 (24.9%) | 94 (39.3%) | <0.001 | 146 (17.8%) | 182 (36.3%) | <0.001 |
aGGT <75th vs. GGT ≥75th in men; bGGT <75th vs. GGT ≥75th in women.
OR and 95% CI of sex-specific quartiles of GGT associated with major CRFs and clustered risk factors. Age, UA, alcohol, ethnicity, and all other risk factors were adjusted when estimating odds ratios (ORs) with 95% confidence intervals (CIs) of each variable.
| Men | Women | |||||||
|---|---|---|---|---|---|---|---|---|
| Q1(<17 U/L) | Q2(17–25 U/L) | Q3(25–43 U/L) | Q4(>43 U/L) | Q1(<11 U/L) | Q2(11–15 U/L) | Q3(15–23 U/L) | Q4(>23 U/L) | |
| CRFs | ||||||||
| Dyslipidemia | 1 (ref) | 1.744 (1.549–1.963)* | 3.061 (2.716–3.450)* | 7.429 (6.486–8.510)* | 1 (ref) | 1.366 (1.201–1.554)* | 2.212 (1.945–2.516)* | 3.434 (3.008–3.922)* |
| Hypertension1 | 1 (ref) | 1.341 (1.153–1.559)* | 1.788 (1.546–2.067)* | 2.611 (2.252–3.028)* | 1 (ref) | 1.206 (1.013–1.436)* | 1.736 (1.468–2.053)* | 2.254 (1.909–2.662)* |
| Hypertension2 | 1 (ref) | 1.317 (1.170–1.483)* | 1.959 (1.741–2.206)* | 3.022 (2.665–3.428)* | 1 (ref) | 1.135 (1.007–1.280)* | 1.607 (1.425–1.813)* | 2.076 (1.833–2.350)* |
| Diabetes | 1 (ref) | 1.446 (1.023–2.045)* | 2.200 (1.591–3.041)* | 4.597 (3.347–6.316)* | 1 (ref) | 3.136 (1.527–6.442)* | 5.483 (2.751–10.931)* | 12.018 (6.108–23.644)* |
| Current smoking | 1 (ref) | 1.233 (1.093–1.391)* | 1.355 (1.201–1.529)* | 1.584 (1.397–1.796)* | 1 (ref) | 1.002 (0.680–1.474)# | 1.161 (0.796–1.692)# | 1.492 (1.032–2.157)* |
| Overweight | 1 (ref) | 2.105 (1.811–2.447)* | 4.172 (3.609–4.823)* | 7.417 (6.388–8.612)* | 1 (ref) | 1.519 (1.290–1.789)* | 2.603 (2.223–3.047)* | 3.853 (3.290–4.512)* |
| clustered risk factors | ||||||||
| 1 | 1 (ref) | 1.660 (1.454–1.895)* | 3.258 (2.788–3.808)* | 7.027 (5.683–8.689)* | 1 (ref) | 1.340 (1.185–1.515)* | 2.407 (2.118–2.736)* | 3.888 (3.377–4.476)* |
| 2 | 1 (ref) | 1.923 (1.693–2.185)* | 3.707 (3.265–4.210)* | 8.206 (7.128–9.447)* | 1 (ref) | 1.657 (1.386–1.982)* | 3.071 (2.589–3.643)* | 5.255 (4.435–6.226)* |
| ≥3 | 1 (ref) | 2.199 (1.804–2.681)* | 4.107 (3.406–4.951)* | 9.456 (7.848–11.392)* | 1 (ref) | 1.911 (1.321–2.764)* | 3.853 (2.727–5.443)* | 7.043 (5.019–9.881)* |
*P < 0.05, #P > 0.05.
1OR and 95% CI of sex-specific quartiles of GGT associated with hypertension defined with JNC7.
2OR and 95% CI of sex-specific quartiles of GGT associated with hypertension defined with 2017 ACC/AHA.
OR and 95% CI of GGT ≥75th associated with major CRFs and clustered risk factors. Age, UA, alcohol, ethnicity, and all other risk factors were adjusted when estimating odds ratios (ORs) with 95% confidence intervals (CIs) of each variable.
| CRFs | Men | Women | ||
|---|---|---|---|---|
| Unadjusted OR (95% CI) GGT ≥75th | Adjusted OR (95% CI) GGT ≥75th | Unadjusted OR (95% CI) GGT ≥75th | Adjusted OR (95% CI) GGT ≥75th | |
| Dyslipidemia | 4.530 (4.084–5.025)* | 3.895 (3.487–4.352)* | 3.439 (3.157–3.745)* | 2.187 (1.985–2.408)* |
| Hypertension1 | 1.999 (1.820–2.195)* | 1.709 (1.536–1.901)* | 2.498 (2.280–2.738)* | 1.483 (1.334–1.649)* |
| Hypertension2 | 2.515 (2.294–2.757)* | 2.122 (1.920–2.344)* | 2.251 (2.074–2.445)* | 1.681 (1.537–1.839)* |
| Diabetes | 2.365 (1.977–2.830)* | 2.573 (2.1100–3.138)* | 4.952 (4.076–6.016)* | 2.904 (2.349–3,591)* |
| Current smoking | 1.573 (1.439–1.720)* | 1.325 (1.201–1.462)* | 1.815 (1.452–2.267)* | 1.365 (1.069–1.745)* |
| Overweight | 3.739 (3.412–4.096)* | 3.165 (2.859–3.504)* | 3.219 (2.953–3.508)* | 2.086 (1.896–2.295)* |
| clustered risk factors | ||||
| 0 | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) |
| 1 | 2.334 (1.892–2.878)* | 2.096 (1.685–2.606)* | 2.804 (2.498–3.148)* | 2.087 (1.841–2.366)* |
| 2 | 6.026 (4.936–7.356)* | 4.853 (3.923–6.002)* | 5.702 (5.052–6.437)* | 3.412 (2.968–3.921)* |
| ≥3 | 13.859 (11.360–16.907)* | 10.843 (8.748–13.441)* | 10.415 (9.013–12.036)* | 5.344 (4.516–6.324)* |
*P < 0.05.
1OR and 95% CI of GGT ≥75th associated with hypertension defined with JNC7.
2OR and 95% CI of GGT ≥75th associated with hypertension defined with 2017 ACC/AHA.
Figure 2The percentage of GGT ≥75th for different numbers of risk factors.